Retinopathy of Prematurity (ROP)

Overview

Retinopathy of prematurity (ROP) is a vasoproliferative retinal disease affecting preterm, low-birth-weight infants, caused by disruption of the normal sequence of retinal vascularization that would otherwise continue in utero until term. It ranges from mild peripheral avascular retina that regresses spontaneously to severe disease with abnormal fibrovascular proliferation that can progress to retinal detachment and permanent blindness if untreated.

Epidemiology & Risk Factors

ROP risk is inversely related to gestational age and birth weight, with the most immature and lowest birth weight infants at greatest risk of severe disease. Prolonged supplemental oxygen exposure, bronchopulmonary dysplasia, and other markers of a more complicated neonatal course are all associated with increased risk and severity.² Standardized screening protocols based on gestational age and birth weight identify infants requiring serial dilated retinal examinations.

Pathophysiology

Normal retinal vascularization proceeds from the optic disc toward the peripheral retina over the course of gestation, reaching the periphery only near term. Premature birth interrupts this process, leaving the peripheral retina avascular. The relatively hyperoxic extrauterine environment (further compounded by supplemental oxygen) suppresses vascular endothelial growth factor (VEGF)-driven vessel growth; when the infant is later returned to a relatively hypoxic state, or as the avascular retina's metabolic demand increases, a compensatory surge in VEGF drives abnormal, disorganized fibrovascular proliferation at the junction between vascularized and avascular retina, which can progress to tractional retinal detachment in severe disease.

Clinical Presentation

ROP itself is asymptomatic and detected only through structured screening of at-risk infants with serial dilated fundus examinations, since by definition affected infants are pre-verbal and too young to report visual symptoms. Disease is staged by the location (zone), extent (clock hours), and severity (stage) of abnormal vascular findings, along with the presence or absence of "plus disease" (vascular dilation and tortuosity indicating more aggressive disease activity).

Exam Findings

• Zone (I, II, or III, based on distance from the optic disc) and stage (1 through 5, reflecting increasing severity of the vascular-avascular junction abnormality) of disease
• Plus disease: posterior retinal vascular dilation and tortuosity, indicating more aggressive, treatment-requiring disease
• Extent of disease measured in clock hours of retinal involvement
• Type 1 ROP (requiring treatment): zone I any stage with plus disease, zone I stage 3 without plus disease, or zone II stage 2 or 3 with plus disease
• Aggressive posterior ROP: a rapidly progressive, severe variant occurring in the most posterior zone I retina, requiring prompt recognition and urgent treatment

Differential Diagnosis

• Familial exudative vitreoretinopathy (FEVR), which can mimic ROP's peripheral avascular retina but occurs in term infants and often has a hereditary pattern
• Norrie disease and other rare genetic vitreoretinopathies presenting with abnormal retinal vascular development
• Persistent fetal vasculature, typically unilateral and associated with a small eye and other structural anomalies rather than the bilateral, symmetric pattern typical of ROP

Management

Type 1 ROP requiring treatment is managed with intravitreal anti-VEGF injection, laser photocoagulation of the avascular retina, or occasionally vitrectomy in advanced disease with retinal detachment. Anti-VEGF therapy is associated with the most favorable long-term refractive outcomes among these modalities: pooled analysis across dozens of studies found anti-VEGF-treated eyes had the least myopic mean spherical equivalent and the lowest prevalence of high myopia, compared to laser photocoagulation, and substantially better outcomes than cryotherapy or vitrectomy, which showed the highest myopic burden.¹ This favorable refractive profile must be weighed against anti-VEGF's own considerations, including the need for prolonged, structured follow-up given the risk of later disease reactivation as retinal vascularization continues after treatment. Emerging biomarker research suggests that tear and serum inflammatory markers (CHI3L1, pentraxin-3) rise stepwise with worsening ROP severity and may eventually help identify infants at risk of a poor neurovascular outcome, potentially supplementing conventional risk factors such as gestational age, birth weight, and bronchopulmonary dysplasia, though this evidence is still early and not yet part of standard screening.²

Complications

• Tractional or combined tractional-rhegmatogenous retinal detachment in advanced, untreated disease
• High myopia and other refractive errors, with the magnitude of risk varying substantially by treatment modality received¹
• Strabismus and amblyopia, more common in infants with a history of ROP even after successful treatment
• Late reactivation of disease after anti-VEGF treatment, given that abnormal retinal vascularization can resume as the peripheral retina continues to develop, necessitating extended follow-up
• Secondary vasoproliferative retinal tumors, a rare late complication reported in eyes with a remote history of ROP among other predisposing retinal conditions

Clinical Pearls

• ROP is asymptomatic and identified only through structured screening — gestational age and birth weight-based screening criteria, not clinical symptoms, determine which infants require serial examinations
• Plus disease (vascular dilation and tortuosity) is a key marker of disease activity and treatment urgency, distinct from zone and stage alone
• Anti-VEGF therapy carries the most favorable long-term refractive profile among current ROP treatments, though it requires prolonged follow-up given the risk of late reactivation¹
• Cryotherapy and vitrectomy, while sometimes necessary in advanced disease, carry the highest risk of significant myopic refractive outcomes among ROP treatments¹
• Emerging tear and serum biomarkers may eventually supplement conventional risk factors for predicting ROP severity and neurovascular prognosis, but remain investigational²

Common Pitfalls

• Failing to enroll an eligible preterm infant in structured ROP screening based on gestational age and birth weight criteria
• Discharging an anti-VEGF-treated infant from follow-up too early, missing a late reactivation of disease
• Treating all ROP treatment modalities as functionally equivalent in terms of long-term visual and refractive outcome, when substantial differences exist between anti-VEGF, laser, cryotherapy, and vitrectomy¹
• Overlooking strabismus and amblyopia screening in children with a history of ROP, even after apparently successful acute treatment
• Relying on investigational biomarker panels in place of established, validated screening and staging criteria²